Sofgen Pharma (PROCF) Stock Price

Sofgen Pharma Price

NASDAQ·CLOSED
0.03USD+0.00 (+0.00 %)
Market closed

Over the last 5 years Sofgen Pharma grew revenue by 2.8% annually, reaching 373.80 M USD. For Sofgen Pharma, the net margin of -18.3% is down versus -3.1% a few years ago. The stock trades about 3,790% above its 52-week low.

Sofgen Pharma stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Sofgen Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sofgen Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sofgen Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sofgen Pharma Stock Price History
DateSofgen Pharma Price
8/3/20260.03 USD
7/30/20260.03 USD
7/29/20260.03 USD
7/28/20260.03 USD
7/27/20260.03 USD
7/24/20260.03 USD
7/23/20260.03 USD
7/22/20260.03 USD
7/21/20260.03 USD
7/20/20260.03 USD
7/17/20260.03 USD
7/16/20260.03 USD
7/15/20260.03 USD
7/14/20260.03 USD
7/13/20260.03 USD
7/10/20260.03 USD
7/9/20260.03 USD
7/8/20260.03 USD
7/7/20260.03 USD
7/6/20260.03 USD
7/4/20260.03 USD
7/2/20260.03 USD
7/1/20260.03 USD
6/30/20260.03 USD
6/29/20260.03 USD
6/26/20260.03 USD
6/25/20260.03 USD
6/24/20260.03 USD
6/23/20260.03 USD
6/22/20260.03 USD
6/18/20260.03 USD
6/17/20260.03 USD
6/16/20260.03 USD
6/15/20260.03 USD
6/12/20260.03 USD
6/11/20260.03 USD
6/10/20260.03 USD
6/9/20260.03 USD
6/8/20260.03 USD
6/5/20260.03 USD
6/4/20260.03 USD
6/3/20260.03 USD
6/2/20260.03 USD
6/1/20260.03 USD
5/29/20260.03 USD
5/28/20260.03 USD
5/27/20260.03 USD
5/26/20260.03 USD
5/22/20260.03 USD
4/22/20260.03 USD
4/21/20260.03 USD
4/20/20260.03 USD
4/17/20260.03 USD
4/16/20260.03 USD
4/15/20260.03 USD
4/14/20260.03 USD
4/13/20260.03 USD
4/10/20260.03 USD
4/9/20260.03 USD
4/8/20260.03 USD
4/7/20260.03 USD
4/6/20260.03 USD
4/2/20260.03 USD
4/1/20260.03 USD
3/31/20260.03 USD
3/30/20260.03 USD
3/27/20260.03 USD
3/26/20260.03 USD
3/25/20260.03 USD
3/24/20260.03 USD
3/18/20260.01 USD
3/17/20260.01 USD
3/16/20260.01 USD
3/13/20260.01 USD
3/12/20260.01 USD
3/11/20260.01 USD
3/10/20260.01 USD
3/9/20260.01 USD
3/6/20260.01 USD
3/5/20260.01 USD
3/4/20260.01 USD
3/3/20260.01 USD
3/2/20260.01 USD
2/27/20260.01 USD
2/26/20260.01 USD
2/25/20260.01 USD
2/24/20260.01 USD
2/23/20260.01 USD
2/20/20260.01 USD
2/19/20260.01 USD
2/18/20260.01 USD
2/17/20260.01 USD
2/13/20260.01 USD
2/12/20260.01 USD
2/11/20260.01 USD
2/10/20260.01 USD
2/9/20260.01 USD
2/6/20260.01 USD
2/5/20260.01 USD
2/4/20260.01 USD
2/3/20260.01 USD
2/2/20260.01 USD
1/30/20260.01 USD
1/29/20260.01 USD
1/28/20260.01 USD
1/27/20260.01 USD
1/26/20260.01 USD
1/23/20260.01 USD
1/22/20260.01 USD
1/21/20260.01 USD
1/20/20260.01 USD
1/16/20260.01 USD
1/15/20260.01 USD
1/14/20260.01 USD
1/13/20260.01 USD
1/12/20260.01 USD
1/9/20260.01 USD
1/8/20260.01 USD
1/7/20260.01 USD
1/6/20260.01 USD
1/5/20260.01 USD
1/2/20260.01 USD
12/31/20250.01 USD
12/30/20250.01 USD
12/29/20250.01 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.03 USD
10/30/20250.03 USD
10/29/20250.03 USD
10/28/20250.03 USD
10/27/20250.03 USD
10/24/20250.03 USD
10/23/20250.03 USD
10/22/20250.03 USD
10/21/20250.03 USD
10/20/20250.03 USD
10/17/20250.03 USD
10/16/20250.03 USD
10/15/20250.03 USD
10/14/20250.03 USD
10/13/20250.03 USD
10/10/20250.03 USD
10/9/20250.02 USD
10/8/20250.02 USD
10/7/20250.02 USD
10/6/20250.02 USD
10/3/20250.02 USD
10/2/20250.02 USD
10/1/20250.02 USD
9/30/20250.02 USD
9/29/20250.02 USD
9/26/20250.02 USD
9/25/20250.02 USD
9/24/20250.02 USD
9/23/20250.02 USD
9/22/20250.02 USD
9/19/20250.02 USD
9/18/20250.02 USD
9/17/20250.02 USD
9/16/20250.03 USD
9/15/20250.03 USD
9/12/20250.03 USD
9/11/20250.03 USD
9/10/20250.03 USD
9/9/20250.03 USD
9/8/20250.03 USD
9/5/20250.03 USD
9/4/20250.02 USD
9/3/20250.02 USD
9/2/20250.02 USD
8/29/20250.02 USD
8/28/20250.03 USD
8/27/20250.03 USD
8/26/20250.02 USD
8/25/20250.02 USD
8/22/20250.02 USD
8/21/20250.02 USD
8/20/20250.02 USD
8/19/20250.02 USD
8/18/20250.02 USD
8/15/20250.02 USD
8/14/20250.02 USD
8/13/20250.02 USD
8/12/20250.02 USD
8/11/20250.02 USD
8/8/20250.02 USD
8/7/20250.02 USD
Access this data via the Eulerpool API

Sofgen Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
324.80 M USD
37.40 M USD
-17.00 M USD
Jan 1, 2020
331.50 M USD
63.10 M USD
-10.40 M USD
Jan 1, 2021
403.74 M USD
65.15 M USD
-106.99 M USD
Jan 1, 2022
403.20 M USD
36.32 M USD
36.13 M USD
Jan 1, 2023
423.75 M USD
0.00 USD
40.34 M USD
Jan 1, 2024
373.80 M USD
-39.27 M USD
-68.30 M USD

Sofgen Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 9:50 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201920202021202220232024
324.00331.00403.00403.00423.00373.00
2.1621.754.96-11.82
56.1757.7057.0758.3156.0351.21
182.00191.00230.00235.00237.00191.00
37.0063.0065.0036.00-39.00
11.4219.0316.138.93-10.46
-17.00-10.00-106.0036.0040.00-68.00
-41.18960.00-133.9611.11-270.00
112.80112.80112.82112.82112.82112.82
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sofgen Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sofgen Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sofgen Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sofgen Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sofgen Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sofgen Pharma stock margins

The Sofgen Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sofgen Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sofgen Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
56.19 %
11.51 %
-5.23 %
Jan 1, 2020
57.71 %
19.03 %
-3.14 %
Jan 1, 2021
56.99 %
16.14 %
-26.50 %
Jan 1, 2022
58.32 %
9.01 %
8.96 %
Jan 1, 2023
56.16 %
0.00 %
9.52 %
Jan 1, 2024
51.23 %
-10.51 %
-18.27 %

Sofgen Pharma Stock Revenue, EBIT, Earnings per Share

The Sofgen Pharma earnings per share therefore indicates how much revenue Sofgen Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
2.88 USD
0.33 USD
-0.15 USD
Jan 1, 2020
2.94 USD
0.56 USD
-0.09 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
3.31 USD
-0.35 USD
-0.61 USD

Sofgen Pharma business model & stock analysis

Sofgen Pharma Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sofgen Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Sofgen Pharma annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sofgen Pharma shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
112.80 M Stocks
Jan 1, 2020
112.80 M Stocks
Jan 1, 2021
112.80 M Stocks
Jan 1, 2022
112.80 M Stocks
Jan 1, 2023
112.80 M Stocks
Jan 1, 2024
112.82 M Stocks

Sofgen Pharma stock splits

In Sofgen Pharma's history, there have been no stock splits.
Price targets and forecasts for Sofgen Pharma are not yet available.

Sofgen Pharma shareholder structure

% Name
0.00001%
State Street Investment Management (US)
State Street Investment Management (US)

Sofgen Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
84.1%
Float Shares
-
Shares Outstanding
-

Sofgen Pharma Executives and Management Board

11 members · avg. age 64 · 9 % women

Management

MA

Ms. Melissa Angelini

Interim Chief Executive Officer, Director · since 2024

DB

Mr. Daniel Bernal

Interim Chief Financial Officer

LA

Mr. Luis Alberto Palacios Aragon (61)

Chief Commercial Officer

Board of Directors

AC

Mr. Alejandro Kostia Weinstein Crenovich (67)

Executive Chairman of the Board

CC

Mr. Claudio Colombano

Executive Director of Manufacturing Operations and Quality

NM

Mr. Nicolas Francisco Weinstein Manieu

Director

MC

Mr. Manuel Claro

Independent Director

AC

Mr. Alberto Correa

Independent Director

CI

Mr. Carlos Iragorri

Independent Director

Frequently asked questions about Sofgen Pharma

8 analysts currently rate the Sofgen Pharma stock: 0 recommend buying, 3 holding and 5 selling.

Converted at the current exchange rate, the Sofgen Pharma share trades at 0.02 EUR (0.03 USD).

The Sofgen Pharma share (PROCF) is listed on 2 stock exchanges, including: NASDAQ (PROC), Frankfurt (9X1.F).

No history available for Sofgen Pharma.

The revenue cannot currently be calculated for Sofgen Pharma.

The profit cannot currently be calculated for Sofgen Pharma.

The P/E ratio cannot be calculated for Sofgen Pharma at the moment.

The P/S cannot be calculated for Sofgen Pharma currently.

The Eulerpool Quality Score for Sofgen Pharma is 1/10.

The ISIN of Sofgen Pharma is LU2376511205. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sofgen Pharma is A3C4K9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sofgen Pharma is PROCF. The ticker symbol is used to trade Sofgen Pharma shares on the stock exchange.

Sofgen Pharma paid dividends every year for the past 0 years.

Sofgen Pharma is assigned to the 'Health' sector.

The dividends of Sofgen Pharma are distributed in USD.

All fundamentals and in-depth analysis of Sofgen Pharma

Our stock analysis for Sofgen Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sofgen Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.